PET/CT WITH 68GA-PSMA-11 IN DETECTION OF PRIMARY TUMOR AND RECURRENCE OF PROSTATE CANCER
PDF (Русский)

Keywords

PET/CT
PROSTATE CANCER

How to Cite

Ryzhkova, D., & Poyda, M. (2018). PET/CT WITH 68GA-PSMA-11 IN DETECTION OF PRIMARY TUMOR AND RECURRENCE OF PROSTATE CANCER. Voprosy Onkologii, 64(6), 799–804. https://doi.org/10.37469/0507-3758-2018-64-6-799-804

Abstract

Purpose: To study the diagnostic value of PET-CT with 68Ga-PSMA-11 in the diagnosis of a primary prostate cancer, preoperative staging, and the detection of recurrence of prostate cancer (PCa).

Methods: 28 patients aged 64.7 ± 8.74 years were included. 10 patients primary prostate cancer, and 18 patients with biochemical recurrence of the disease after radical treatment were examined. All patients underwent PET-CT with 68Ga-PSMA-11 according the whole body protocol. Interpretation of images was performed visually and quantitatively by calculation of SUL max.

Results: High focal or diffuse 68Ga-PSMA-11 uptake was found in prostate parenchyma in patients with primary prostate cancer. Additionally metastases in regional lymph nodes were diagnosed in 4 patients and bone metastases were found in one patient. The correlation between 68Ga-PSMA-11 uptake level and Gleason index in the primary tumor (R Spearmen = 0.25, p = 0.57) was not observed. PET-positive results were obtained in 14 patients and PET-negative results in 4 patients with biochemical recurrence of PCa. The relationship between the frequency of PET-positive results and Gleason index was not revealed (R Spearmen = 0.2, p = 0.39). We found a weak but significant correlation between the frequency of PET-positive results and the prostate tumor stage according to the T category (R Spearmen = 0.49, p = 0.049). In patients with low values of PSA (less than 1.0 ng/ml) in 4 out of 9 cases, PET-negative results were obtained. In patients with PSA level more than 1.0 ng/ml PET-positive results were obtained in all cases.

Conclusions: PET/CT with 68Ga-PSMA-11 allows to diagnose the primary prostate cancer, to establish the stage of the disease in categories N and M, and also to determine the localization and dissemination of the tumor in patients with biochemical recurrence of prostate cancer. The relationship between 68Ga-PSMA-11 uptake in primary tumor and Gleason index was not found. The probability of obtaining PET-positive results in cases of biochemical recurrence is affected by a PSA level above 1 ng/ml and a high stage of the disease according to the T category (T3-T4).

https://doi.org/10.37469/0507-3758-2018-64-6-799-804
PDF (Русский)

References

Игнатова М.В., Тлостанова М.С., Станжевский А.А. Анализ диагностических возможностей ПЭТ/КТ с 68Ga-ПСМА в группе пациентов с разной степенью дифференцировки рака предстательной железы // Лучевая диагностика и терапия. - 2018. - Т. 9. - № 1. - С. 138-144.

Лишманов Ю.Б., Чернов В.И. и др. Национальное руководство по радионуклидной диагностике. - Томск: СТТ, 2010. - Т. 1. - 290 с.

Пахомов А.Ю., Тлостанова М.С., Станжевский А.А. Сочетанное применение ПЭТ/КТ с 11С-холином и 68Ga-ПСМА у больных биохимическим рецидивом рака предстательной железы // Лучевая диагностика и терапия. - 2018. - Т. 9. - № 1. - С. 188-189.

Пурсанова Д.М. ПЭТ/КТ с 11С-холином в ранней диагностике прогрессирования рака предстательной железы. Дисс.. канд. мед. наук. - Москва: ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России, 2015.

Bouchelouche K., Turkbey B., Choyke, P.L. PSMA PET/CT and Radionuclide Therapy in Prostate Cancer // Semin. Nucl. Med. - 2016. - Vol. 46. - P. 522-535.

Castellucci P., Picchio M. 11C-choline PET/CT and PSA kinetics // Eur. J. Nucl. Med. Mol. Imaging. - 2013. - Vol. 40. - Suppl1. - S36-40.

Ferlay J., Soerjomataram I., Ervik M. et al. GLOBOCAN 2012 v1.0: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Электронный ресурс]. Lyon, France: International Agency for Research on Cancer. - 2013. - URL: http://globocan.iarc.fr, дата обращения 15.07.2018.

Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2008 // CA. Cancer. J. Clin. - 2008. - Vol. 58(2). - P. 71-96.

Krause B.J., Souvatzoglou M., Tuncel M. et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. - 2008. - Vol. 35(1). - P 18-23.

Heidenreich A., Bastian PJ., Bellmunt J. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013 // Eur. Urol. - 2014. - Vol. 65(1). - P. 124-137.

Perera M., Papa N., Christidis D. et al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis // Eur. Urol. - 2016. - Vol. 70. - P. 926-937.

Rajasekaran S.A., Anilkumar G., Oshima E. et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen // Mol. Biol. Cell. - 2003. -Vol. 14. - P. 4835-4845.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2018